Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...

Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and a price target of $33, down ...

Denali Therapeutics DNLI reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus ...

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...

In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.

Denali Therapeutics DNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...